MedTrace Logo

Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

NCT05658237 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-15

No results posted yet for this study

Summary

The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy.

The main question it aims to answer are:

• Percentage of changes in the chorioretinal atrophic area

Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy.

Researchers will compare non-therapeutic eye to see if the changes is significant different.

Conditions

  • Myopic Chorioretinal Atrophy

Interventions

PROCEDURE

Pars plana vitrectomy

One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.

Sponsors & Collaborators

  • PharmaBio Corporation

    lead INDUSTRY

Principal Investigators

  • Hitoshi Kusano, M.D. · PhamaBio Coorporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-17
Primary Completion
2026-01-31
Completion
2026-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658237 on ClinicalTrials.gov